StockData
Incannex Healthcare Inc. logo

Incannex Healthcare Inc. (IXHL) company profile

IXHLNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$1.74−0.19 (-9.84%)

Close on Nov 17, 2026Market cap $21.83MP/E –Yield –

About Incannex Healthcare

Pharmaceutical Preparations, SIC 2834

Incannex is a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious, chronic conditions. Its pipeline includes IHL-42X, an oral combination therapy in clinical development for obstructive sleep apnea, and PSX-001, a synthetic psilocybin treatment administered alongside psychotherapy for generalized anxiety disorder. The company is also evaluating IHL-675A, an oral combination targeting inflammatory conditions including rheumatoid arthritis. These investigational programs aim to provide alternative pharmacological treatments for patients who are underserved by existing care options.

The company operates clinical trials across sites in the United States and has conducted early-stage studies and collaborative research in Australia. It also participates in a joint venture operating a psychedelic-assisted therapies services clinic in Melbourne, Australia. The provided text mentions manufacturing partnerships in the United States but does not identify the location of the corporate headquarters.

Summary of the business section of Incannex Healthcare's latest annual report, written by StockData.

Company profile

Company

Legal name
Incannex Healthcare Inc.
Headquarters
Norwest Nsw, Australia
Address
8 Century Circuit, Ste. 105
Phone
61 409 840 786
Employees
12, Jun 30, 2026
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
June 30
Auditor
GRANT THORNTON AUDIT PTY LTD, Perth, Australia

Stock & identifiers

Ticker
IXHL
Exchange
Nasdaq
IPO date
Mar 2, 2022
Shares outstanding
13M, Sep 24, 2026
Public float
$123.50M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-30 reverse, Feb 27, 2026
SEC CIK
1873875
CUSIP
45333F208
ISIN
US45333F2083
FIGI
BBG01J0814Y2
Share class FIGI
BBG01J0814Z1
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Joel LathamCEO and President, Director24,186,177
Joseph SwanCFO, Treasurer and Secretary921,358
George AnastassovDirector2,456,677
Troy ValentineDirector12,339,120
Peter WiddowsDirector1,957,803
Robert ClarkDirector1,786,956

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Joel Latham
Chief Executive Officer
$656.46K$297.69K–$173.59K$1.13M-82%
Joseph Swan
Chief Financial Officer
$150.65K$30.13K–$20.41K$201.19K-24%
Luigi M. Barbato
Chief Medical Officer
$264.06K–$233.10K–$497.17K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of June 30, 2026, we had twelve full-time employees, including eight in R&D and four in general management and administration.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?